Abstract:4067 Background: Peritoneal metastasis is detected as any part of the metastasis/recurrence pattern in most stage III patients after radical surgery and appears to be the most life-threatening type of metastasis in patients with advanced gastric cancer. Previous studies have suggested that the molecular detection of cancer-specific carcinoembryonic antigen (CEA) mRNA levels in the peritoneal lavage has superior value for postoperative peritoneal recurrence in patients with advanced gastric cancer. The efficacy of intraperitoneal (IP) chemotherapy has been shown in gastric cancer patients with peritoneal metastasis. Methods: Eligibility criteria included pathologically confirmed stage III gastric adenocarcinoma after radical surgery, and no prior chemotherapy. Patients were first divided into CEA-positive group and CEA-negative group according to the CEA mRNA lever in the peritoneal lavage, and then in each group patients were randomized 1:1 to intraperitoneal (IP) arm and intravenous (IV) arm. Patients in IP arm received 2 cycles intraperitoneal docetaxel with oral S-1 and 4 cycles intravenous docetaxel with oral S-1, while patients in IV arm received 6 cycles intravenous docetaxel with oral S-1. The primary endpoint was 1-year disease-free survival rate (1-year DFS rate). Secondary endpoints were disease-free survival, overall survival, and safety. Result: Between April 2015 and June 2016, 161 patients were enrolled and 158 patients included in the efficacy analysis. 65 patients had positive CEA mRNA in peritoneal lavage and 93 had negative CEA mRNA. Baseline patient characteristics were balanced between IP arm and IV arm in both CEA-positive group and CEA-negative group. The 1-year DFS rate for CEA-positive group and CEA-negative group were 41% and 89%, respectively (p < 0.01). In CEA-negative group, the 1-year DFS rate for IP arm and IV arm were 86% and 89%, respective (P = 0.720). In CEA-positive group, the 1-year DFS rate for IP arm and IV arm were 66% and 41%, respective (P = 0.035). Both regimens were tolerable. Conclusion: The primary analysis showed the statistical superiority and clinical efficacy of the multi-route (intraperitoneal/intravenous/oral) regimen for patients with positive CEA mRNA in peritoneal lavage. It suggested clinical efficacy. Clinical trial information: ChiCTR-IPR-15006202.

The Phase II Clinical Trial of Seratia Marcescens Anticancer Vaccine (S311) for Malignant Pleural Effusions

Prospective, multicenter clinical study of rmhTNF-NC injection in the treatment of Chinese malignant pleural effusion or peritoneal effusion patients

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Effects of intrapleural therapy on 96 patients with malignant pleural effusion

Sintilimab in Patients with Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Chemotherapy: A Randomized, Open-Label Phase II Trial (ORIENT-2).

A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma

Effect of Interleukin-2 and PDD in Treatment of Malignant Pleural Effu Sion

Therapeutic Effect of Tumor Infiltrating Lymphocyte Plus Interleukin-2 Intrapleural Injection on Advanced Cancer Patients with Malignant Pleural Effusion

A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma

Phase III Study of Intraperitoneal/intravenous Adjuvant Chemotherapy Compared Intravenous Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer.

Therapeutical Effect of Intrapleural Perfusion with Hyperthermic Chemotherapy on Malignant Pleural Effusion under Video-Assisted Thoracoscopic Surgery

Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion

Phase II Study of S-1 Plus Cisplatin As First-Line Therapy in Patients with Metastatic Esophageal Carcinoma

Treatment of Malignant Serosal Effusion Through Injecting Donor Lymphocytes into Serosal Cavity

Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study

Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial

Phase Ⅱ clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion

Clinical Efficacy of Intra-Cavitary Infusions of Autologous Dendritic Cell/cytokine-Induced Killer Cell Products for the Treatment of Refractory Malignant Pleural Effusions and Ascites.

Efficacy and Safety of Recombinant Human Tumor Necrosis Factor Application for the Treatment of Malignant Pleural Effusion Caused by Lung Cancer

P16.05 Exploratory Study of Sintilimab Intrapleural Therapy for NSCLC-Mediated Malignant Pleural Effusion

Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials